FDA Guidances Focus on Trials of Crohn’s Disease, Ulcerative Colitis Drugs
May 31, 2022
Trials of drugs to treat Crohn’s disease should add reduction of intestinal inflammation to their symptom-relief endpoints, according to an FDA draft guidance released in tandem with a draft guidance for conducting ulcerative colitis trials.